Off-label therapies: what is their future?
Many studies presented at the Congress hint at promising treatments for rare sarcomas but access to effective treatments remains a challenge
ClarIDHy trial reports a small improvement in progression-free survival
Targeting isocitrate dehydrogenase 1 mutations in cholangiocarcinoma is a promising strategy
Chemotherapy plus endocrine therapy increases long-term recurrence-free survival in women with high-risk HR+ breast cancer
Results from TAILORx trial presented at ESMO 2019
Targeting HER2 amplifications in metastatic colorectal cancer: searching for the most active combination therapy?
Mixed results from the the HERACLES-B, TRIUMPH and MOUNTAINEER trials
Closing the clinician–patient gap with patient-reported outcomes
PROs encourage patient-centred cancer care
‘Living’ anticancer medicines: has a new era started?
The benefits of adoptive T-cell therapy—where T-cells are given to induce a specific immune response—are moving closer to reality for patients with solid tumours
Two CDK 4/6 inhibitors prolong survival in HR+/HER2- breast cancer in pre- and post-menopausal women
Results from the MONARCH 2 and MONALEESA-3 trials